BTIG Trims PT on AtriCure (ATRC) to $19; Management 'Disconnect' Causes Concern
Tweet Send to a Friend
BTIG cut its price target on Buy-rated AtriCure (NASDAQ: ATRC) from $34 down to $19 after the company reported Q2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
